Justin M. Roberts

发表

Phthalimide conjugation as a strategy for in vivo target protein degradation

James E. Bradner, Amanda Souza, Dennis L. Buckley, 2015, Science.

Selective Target Protein Degradation via Phthalimide Conjugation

Dennis L. Buckley, J. Bradner, G. Winter, 2015 .

MELK is not necessary for the proliferation of basal-like breast cancer cells

Nathanael S Gray, Behnam Nabet, Dennis L. Buckley, 2017, eLife.

The dTAG system for immediate and target-specific protein degradation

James E. Bradner, Kwok-Kin Wong, Amanda Souza, 2018, Nature Chemical Biology.

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

James E. Bradner, Jason S. Carroll, X. Shirley Liu, 2015, Nature.

Genome-wide CRISPR screens reveal multitiered mechanisms through which mTORC1 senses mitochondrial dysfunction

D. Sabatini, Jose M. Orozco, K. J. Condon, 2020, Proceedings of the National Academy of Sciences.

Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably Enhanced Redox-Triggered Ferrocenium Activity in Cells

J. Bradner, S. Coles, G. Tizzard, 2017 .

A role for site-specific phosphorylation of mouse progesterone receptor at serine 191 in vivo.

D. Edwards, N. Weigel, F. DeMayo, 2014, Molecular endocrinology.

Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors.

J. Bradner, O. Wiest, Robert M. Williams, 2017, Israel journal of chemistry.

Dynamics of the Tec‐family tyrosine kinase SH3 domains

R. Joseph, A. Andreotti, T. Smithgall, 2016, Protein science : a publication of the Protein Society.

Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.

M. McKeown, Xiang Xu, Dennis L. Buckley, 2018, ACS chemical biology.

BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment.

Christopher J. Ott, Charles Y. Lin, Dennis L. Buckley, 2017, Molecular cell.

Transcription control by the ENL YEATS domain in acute leukemia

Neville E. Sanjana, S. Orkin, Dennis L. Buckley, 2016, Nature.

Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014).

J. Qi, J. Bradner, Justin M. Roberts, 2015, Pharmaceutical patent analyst.

Transcription control by the ENL YEATS domain in acute leukemia

S. Orkin, Dennis L. Buckley, J. Bradner, 2016, Nature.

Structure-guided design and development of potent and selective dual BRD4/PLK1 inhibitors

Lei, Xiaofeng, Shuai Liu, 2018 .

Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.

Wei Zhang, Shuai Liu, Xiaofeng Zhang, 2018, Journal of medicinal chemistry.

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors

Yun Song, Mingxuan Wu, Jeffrey J Gray, 2018, Nature Communications.

Chromosome compartmentalization alterations in prostate cancer cell lines model disease progression

Jacob T. Sanders, R. McCord, Yang Xu, 2021, The Journal of cell biology.

Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG

Jeffery A. Dodge, C. Coarfa, N. Weigel, 2017, Oncotarget.

The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.

M. Ittmann, Jianghuai Wang, N. Weigel, 2014, Endocrinology.

BET Bromodomain Protein s Function as Master Transcription Elongation Factors Independent of CDK 9 Recruitment Graphical

Christopher J. Ott, Charles Y. Lin, Dennis L. Buckley, 2017 .

Design and Characterization of Bivalent BET Inhibitors

J. Bradner, H. Seo, S. Dhe-Paganon, 2016, Nature chemical biology.

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

B. Bernstein, L. Zou, J. Teruya-Feldstein, 2018, Cancer cell.

Back Cover: Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET‐BRET (ChemMedChem 23/2016)

Luke W. Koblan, Shuai Liu, Dennis L. Buckley, 2016 .

Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET‐BRET

Christopher J. Ott, Luke W. Koblan, Wei Zhang, 2016, ChemMedChem.

Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells

C. Coarfa, N. Weigel, A. Sreekumar, 2015, Oncotarget.

Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.

B. Bernstein, L. Zou, J. Teruya-Feldstein, 2018, Cancer cell.

Fibroblast growth factors signaling in bone metastasis

E. Vazquez, C. Logothetis, P. Corn, 2020, Endocrine-related cancer.

A Bead‐Based Proximity Assay for BRD4 Ligand Discovery

J. Bradner, Justin M. Roberts, 2015, Current protocols in chemical biology.

Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors

Jeffrey J. Gray, Shourya S. Roy Burman, J. Jeliazkov, 2018, Nature Communications.

Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

Clifford A. Meyer, Henry W. Long, Christopher J. Ott, 2015, Nature.

Dynamics of the Tec‐family tyrosine kinase SH3 domains

R. Joseph, A. Andreotti, T. Smithgall, 2016, Protein science : a publication of the Protein Society.